全球癌症疫苗市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計癌症疫苗市場將從 2025 年的 106.7 億美元成長到 2034 年的 277.5 億美元，2026 年至 2034 年的複合年成長率為 11.21%。

隨著研究人員致力於開發用於癌症預防和治療的創新免疫療法，全球癌症疫苗市場正受到廣泛關注。癌症疫苗透過刺激免疫系統識別並攻擊癌細胞發揮作用，提供了一種靶向性強且創傷性小的治療方法。全球癌症發生率的上升以及對先進治療方法日益成長的需求，都推動了該市場的擴張。

市場的主要驅動力之一是免疫療法和生物技術研究的快速發展。製藥公司和研究機構正大力投資癌症疫苗的研發，用於治療和預防癌症。對腫瘤生物學和免疫反應的深入了解，使得開發靶向特定癌症抗原的疫苗成為可能，與傳統治療方法相比，這些疫苗圖更高的療效和更低的副作用。

癌症疫苗市場前景廣闊，這得益於正在進行的臨床試驗和個人化醫療領域的突破性進展。 mRNA疫苗和聯合治療等新興技術可望徹底改變癌症治療。隨著醫療系統擴大採用創新免疫療法，癌症疫苗將在下一代癌症治療中發揮關鍵作用。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球癌症疫苗市場：依疫苗類型分類

• 市場分析、洞察與預測
• 預防性癌症疫苗
• 用於治療的癌症疫苗
• 其他

第5章：全球癌症疫苗市場：依適應症類型分類

• 市場分析、洞察與預測
• 攝護腺癌
• 膀胱癌
• 黑色素瘤
• 子宮頸癌
• 其他

第6章 全球癌症疫苗市場：依技術類型分類

• 市場分析、洞察與預測
• 重組癌症疫苗
• 全細胞癌症疫苗
• 病毒載體和DNA癌症疫苗
• 其他技術

第7章 全球癌症疫苗市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Merck & Co. Inc
  • GSK Plc
  • Dendreon Pharmaceuticals LLC
  • Dynavax Technologies Corporation
  • Ferring BV
  • Amgen Inc
  • Moderna Inc
  • Sanofi
  • AstraZeneca
  • Bristol Myers Squibb

The Cancer Vaccines Market size is expected to reach USD 27.75 Billion in 2034 from USD 10.67 Billion (2025) growing at a CAGR of 11.21% during 2026-2034.

The Global Cancer Vaccines Market is gaining significant attention as researchers focus on developing innovative immunotherapy solutions to prevent and treat cancer. Cancer vaccines work by stimulating the immune system to recognize and attack cancer cells, offering a targeted and potentially less invasive treatment approach. Increasing global cancer incidence and growing demand for advanced treatment options are contributing to the expansion of this market.

One of the major drivers of the market is the rapid advancement of immunotherapy and biotechnology research. Pharmaceutical companies and research institutions are investing heavily in the development of therapeutic and preventive cancer vaccines. Improved understanding of tumor biology and immune responses has enabled the creation of vaccines that target specific cancer antigens, improving treatment effectiveness and reducing side effects compared to conventional therapies.

The future of the cancer vaccines market looks promising with ongoing clinical trials and breakthroughs in personalized medicine. Emerging technologies such as mRNA-based vaccines and combination therapies are expected to revolutionize cancer treatment. As healthcare systems increasingly adopt innovative immunotherapy solutions, cancer vaccines are likely to play a vital role in the next generation of oncology treatments.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Vaccine Type

• Preventive Cancer Vaccines
• Therapeutic Cancer Vaccines
• Others

By Indication Type

• Prostate Cancer
• Bladder Cancer
• Melanoma
• Cervical Cancer
• Other

By Technology Type

• Recombinant Cancer Vaccines
• Whole-cell Cancer Vaccines
• Viral Vector and DNA Cancer Vaccines
• Other Technologies

COMPANIES PROFILED

• Merck Co Inc, GSK plc, Dendreon Pharmaceuticals LLC, Dynavax Technologies Corporation, Ferring BV, Amgen Inc, Moderna Inc, Sanofi, AstraZeneca, Bristol Myers Squibb
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CANCER VACCINES MARKET: BY VACCINE TYPE 2022-2034 (USD MN and Million Doses)

• 4.1. Market Analysis, Insights and Forecast Vaccine Type
• 4.2. Preventive Cancer Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.3. Therapeutic Cancer Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 5. GLOBAL CANCER VACCINES MARKET: BY INDICATION TYPE 2022-2034 (USD MN and Million Doses)

• 5.1. Market Analysis, Insights and Forecast Indication Type
• 5.2. Prostate Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.3. Bladder Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.4. Melanoma Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.5. Cervical Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.6. Other Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 6. GLOBAL CANCER VACCINES MARKET: BY TECHNOLOGY TYPE 2022-2034 (USD MN and Million Doses)

• 6.1. Market Analysis, Insights and Forecast Technology Type
• 6.2. Recombinant Cancer Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.3. Whole-cell Cancer Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.4. Viral Vector and DNA Cancer Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.5. Other Technologies Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 7. GLOBAL CANCER VACCINES MARKET: BY REGION 2022-2034 (USD MN and Million Doses)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.2.1 By Vaccine Type
  • 7.2.2 By Indication Type
  • 7.2.3 By Technology Type
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.3.1 By Vaccine Type
  • 7.3.2 By Indication Type
  • 7.3.3 By Technology Type
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.4.1 By Vaccine Type
  • 7.4.2 By Indication Type
  • 7.4.3 By Technology Type
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.5.1 By Vaccine Type
  • 7.5.2 By Indication Type
  • 7.5.3 By Technology Type
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.6.1 By Vaccine Type
  • 7.6.2 By Indication Type
  • 7.6.3 By Technology Type
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CANCER VACCINES INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Merck & Co. Inc
  • 9.2.2 GSK Plc
  • 9.2.3 Dendreon Pharmaceuticals LLC
  • 9.2.4 Dynavax Technologies Corporation
  • 9.2.5 Ferring B.V
  • 9.2.6 Amgen Inc
  • 9.2.7 Moderna Inc
  • 9.2.8 Sanofi
  • 9.2.9 AstraZeneca
  • 9.2.10 Bristol Myers Squibb